Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
crispr
5
×
detroit blog main
detroit top stories
glaxosmithkline
5
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
eli lilly
fda
indiana blog main
indiana top stories
clinical trials
gene editing
gene therapy
ipo
abbvie
alzheimer's disease
baricitinib
biogen
cancer
What
bio
roundup
crispr
new
companies
moves
remains
therapeutics
week
allogene
approval
big
biogen’s
biopharma
biopharmaceutical
black
bosley's
bosley’s
bridge
bucks
cancer
cas
ceo
congress
congressional
continue
convo
crime
debut
departure
diamond
diamond’s
diversity
drug
earlier
editas
executives
exit
failures
feud
Language
unset
Current search:
glaxosmithkline
×
crispr
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More